HER2-Mutant NSCLC Clinical Trial Landscape

Key trials in HER2-mutant NSCLC

The HER2-mutant NSCLC pipeline is among the most active in all targeted lung cancer therapy as of 2026. The table below reflects recruiting trials as of early 2026; DataLookout monitors ClinicalTrials.gov daily for new registrations and status changes.

Sources: ClinicalTrials.gov. DataLookout monitors for new registrations and status updates daily. Table reflects recruiting trials as of early 2026. 12+ HER2-mutant NSCLC trials are actively recruiting globally.

HER2 mutations in NSCLC: biology, epidemiology, and historical context

HER2 (ERBB2) is a receptor tyrosine kinase in the ErbB family, most famous for its role in breast cancer where amplification or overexpression drives approximately 15–20% of tumors. In NSCLC, the relevant alteration is different: activating somatic mutations in the HER2 kinase domain, predominantly exon 20 insertions, which lock the kinase in a constitutively active conformation. HER2 exon 20 insertions occur in approximately 2–3% of NSCLC — translating to an estimated 10,000–15,000 new patients per year in the United States alone.

The most common HER2 exon 20 insertion is A775_G776insYVMA, accounting for approximately 20–30% of all HER2 exon 20 insertions in lung cancer. Other common insertions include P780_Y781insGSP and G778_P780dup. The insertion site within exon 20 may influence both the degree of kinase activation and the structural accessibility of the ATP-binding pocket to different TKI chemotypes — a consideration that has driven selectivity engineering in drugs like zongertinib and NVL-330.

T-DXd (Enhertu): the first approved therapy for HER2-mutant NSCLC

Trastuzumab deruxtecan (T-DXd, Enhertu) is an antibody-drug conjugate (ADC) developed jointly by Daiichi Sankyo and AstraZeneca. It consists of a trastuzumab antibody (targeting HER2 extracellular domain), a cleavable tetrapeptide linker, and a topoisomerase I inhibitor payload (DXd, a derivative of exatecan). T-DXd exploits a "bystander effect" — the released payload can diffuse into neighboring cells, providing activity even in tumors with heterogeneous HER2 expression.

T-DXd's approval represented a paradigm shift in HER2-mutant NSCLC — before it, no targeted agent had achieved consistent ORRs above ~30% in this setting. Previous attempts with pan-HER TKIs (afatinib, neratinib, dacomitinib) and HER2 antibodies (trastuzumab, pertuzumab) had largely failed, leading to skepticism about targetability of HER2 mutations in lung cancer. The DESTINY-Lung02 results demonstrated that the ADC mechanism — delivering a cytotoxic payload to HER2-expressing cells regardless of the specific mutation — could overcome the kinase-selectivity challenges of small-molecule TKIs.

T-DXd ILD: a critical safety consideration

Interstitial lung disease (ILD) / pneumonitis is the most clinically significant adverse event associated with T-DXd across tumor types. In DESTINY-Lung02, drug-related ILD occurred in 26% of patients at 6.4 mg/kg and 12% at the approved 5.4 mg/kg dose, with 2 fatal ILD events at the higher dose. Active monitoring for ILD is mandatory in T-DXd-treated patients: CT chest imaging at baseline and periodic intervals, prompt investigation of any new respiratory symptoms, and appropriate dose modification or discontinuation. Oncologists managing NSCLC patients on T-DXd must have established protocols for ILD surveillance and management.

Zongertinib (BI 1810631): the oral TKI challenging T-DXd

Zongertinib (Boehringer Ingelheim) is a next-generation, irreversible, highly selective HER2-targeted TKI designed to address the major limitation of earlier pan-HER TKIs in HER2-mutant NSCLC: EGFR wild-type toxicity. Pan-HER TKIs like afatinib, neratinib, and poziotinib inhibit both EGFR and HER2, causing dose-limiting diarrhea and rash through EGFR inhibition in the GI tract and skin. Zongertinib's selectivity profile — potent HER2 inhibition with sparing of EGFR wild-type — is intended to enable a tolerable therapeutic index at doses sufficient for clinical efficacy.

Beamion LUNG-2 (NCT06151574): Phase 3 registration trial

Beamion LUNG-2 is a global Phase 3 randomized trial comparing zongertinib versus standard of care (which includes T-DXd and chemotherapy as options) in previously treated advanced HER2-mutant NSCLC. This is the first Phase 3 trial directly comparing an oral HER2 TKI against T-DXd, and its results will define whether selective oral TKI therapy can match or exceed the efficacy of the approved ADC in the second-line setting. If positive, zongertinib would become the first oral targeted therapy specifically approved for HER2-mutant NSCLC in the post-platinum second-line setting.

Beamion LUNG-3 (NCT07195695): adjuvant setting

Beamion LUNG-3 is a Phase 3 adjuvant trial comparing zongertinib versus standard treatment (including observation or chemotherapy) following complete surgical resection of HER2-mutant NSCLC. This trial mirrors the adjuvant development path in ALK+ NSCLC (lorlatinib ALINA), EGFR-mutant NSCLC (osimertinib ADAURA), and ROS1+ NSCLC (taletrectinib TRUST-IV). Given the OS benefit demonstrated by adjuvant osimertinib in EGFR-mutant NSCLC, the hypothesis that adjuvant targeted TKI therapy can prevent recurrence in HER2-mutant NSCLC is well-supported by analogy.

Competing HER2-targeted agents in Phase 3

Sevabertinib (BAY 2927088, Bayer)

Sevabertinib is an oral, selective HER2/EGFR inhibitor in development by Bayer for HER2-mutant NSCLC. It selectively targets mutant EGFR (exon 20 insertions) and HER2 (exon 20 insertions) while sparing EGFR wild-type — a similar selectivity engineering approach to zongertinib. Phase 1/2 data showed an ORR of ~53% in pretreated HER2-mutant NSCLC, motivating the Phase 3 SOLSTICE trial (NCT06452277) comparing sevabertinib versus standard of care. The competitive dynamics between sevabertinib, zongertinib, and T-DXd will define second-line HER2-mutant NSCLC treatment over the next 2–3 years.

SHR-A1811 (Jiangsu HengRui)

SHR-A1811 is a HER2-targeted ADC developed by HengRui Medicine, incorporating a topoisomerase I inhibitor payload similar to T-DXd but with a potentially differentiated linker-payload system. A Phase 3 trial (NCT06430437) is comparing SHR-A1811 versus standard first-line therapy in HER2-mutant NSCLC — an earlier line of therapy than T-DXd's current approved indication (previously treated). If positive, SHR-A1811 could establish an ADC as the preferred first-line therapy for HER2-mutant NSCLC, analogous to how T-DXd has transformed the second-line setting.

Next-generation agents: NVL-330 and beyond

Nuvalent — the company developing neladalkib (ALK) and NVL-520 (ROS1) — has also entered the HER2-mutant NSCLC space with NVL-330, a highly selective HER2-targeted TKI in Phase 1 development (HEROEX-1, NCT06521554). Nuvalent's engineering approach, which has produced some of the most selective and CNS-penetrant kinase inhibitors in oncology, is now being applied to HER2 — particularly targeting HER2 exon 20 insertions with the selectivity-for-mutant-over-wild-type profile that has differentiated the company's ALK and ROS1 programs.

BlossomHill Therapeutics' BH-30643 and Pierre Fabre's STX-721/PFL-721 represent additional entrants targeting both EGFR and HER2 exon 20 insertions — reflecting the structural similarity between these two alterations and the opportunity to develop drugs active against both subgroups simultaneously. Given that EGFR exon 20 insertions (amivantamab-approved) and HER2 exon 20 insertions are biologically related but clinically distinct, dual-targeting agents face a complex regulatory and commercial path.

HER2-mutant vs. HER2-amplified vs. HER2-overexpressing NSCLC: three distinct populations

The HER2 landscape in NSCLC involves three molecularly distinct populations that respond differently to anti-HER2 therapies, and which are the subject of separate clinical programs:

• HER2 exon 20 insertions (~2–3% of NSCLC): The primary focus of this page. Activating kinase domain mutations. T-DXd approved; zongertinib and sevabertinib in Phase 3.
• HER2 amplification (~3–6% of NSCLC): Gene copy number increase, often without mutation. Generally lower HER2 protein levels than breast cancer. Sensitivity to T-DXd and TKIs is less predictable than for mutations. Active investigation in T-DXd combination trials.
• HER2 overexpression (IHC 3+, ~7–15% of NSCLC): High protein expression without necessarily harboring mutations or amplification. T-DXd is being studied in Phase 3 trials (NCT06899126) for first-line HER2-overexpressing NSCLC — an indication distinct from the approved HER2-mutant label.

These distinctions matter for clinical trial eligibility, regulatory strategy, and commercial planning. A drug approved for HER2-mutant NSCLC (mutation-driven) has a different label and patient population than one approved for HER2-overexpressing NSCLC. Pharma teams monitoring this space should track all three populations separately while recognizing their biological overlap.

Related clinical trials and monitoring resources

HER2-mutant NSCLC is part of the broader targeted therapy revolution in lung cancer, with particularly close connections to EGFR exon 20 biology. DataLookout monitors related areas including:

• NSCLC clinical trials — full non-small cell lung cancer pipeline, all molecular subgroups
• EGFR mutant lung cancer clinical trials — largest NSCLC targeted therapy population; exon 20 insertions share biological features with HER2 exon 20
• ALK-positive lung cancer clinical trials — parallel TKI development trajectory; Nuvalent active in both ALK and HER2
• ROS1-fusion NSCLC clinical trials — another rare (~1–2%) targetable NSCLC subgroup; Nuvalent active in ROS1 and HER2
• RET-fusion NSCLC clinical trials — comparative rare oncogene subgroup; similar epidemiology and no-smoker enrichment

Frequently asked questions